TELA Bio (NASDAQ:TELA) CEO Heather Getz Acquires 15,000 Shares

Posted by Geri Gentry on Aug 18th, 2026

TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) CEO Heather Getz bought 15,000 shares of TELA Bio stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average price of $0.70 per share, for a total transaction of $10,500.00. Following the completion of the acquisition, the chief executive officer directly owned 520,000 shares of the company’s stock, valued at $364,000. The trade was a 2.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

TELA Bio Trading Up 0.9%

NASDAQ:TELA opened at $0.65 on Tuesday. TELA Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $2.00. The stock has a market capitalization of $29.18 million, a price-to-earnings ratio of -0.84 and a beta of 1.34. The firm has a fifty day simple moving average of $0.78 and a two-hundred day simple moving average of $0.80. The company has a current ratio of 2.99, a quick ratio of 2.38 and a debt-to-equity ratio of 8.82.

TELA Bio (NASDAQ:TELA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $19.29 million for the quarter, compared to analysts’ expectations of $20.01 million. TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. Analysts expect that TELA Bio, Inc. will post -0.76 EPS for the current fiscal year.

Institutional Investors Weigh In On TELA Bio

Large investors have recently made changes to their positions in the company. Citadel Advisors LLC lifted its stake in shares of TELA Bio by 161.3% during the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after buying an additional 21,781 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of TELA Bio in the 4th quarter worth $48,000. Susquehanna International Group LLP increased its stake in TELA Bio by 551.2% during the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after acquiring an additional 72,594 shares during the last quarter. UP Strategic Wealth Investment Advisors LLC purchased a new position in TELA Bio during the second quarter worth $91,000. Finally, Renaissance Technologies LLC grew its holdings in TELA Bio by 101.4% during the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after purchasing an additional 64,800 shares during the last quarter. 94.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, TELA Bio presently has an average rating of “Hold” and a consensus target price of $2.20.

Check Out Our Latest Report on TELA

TELA Bio Company Profile

(Get Free Report)

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.